Tildrakizumab - Almirall/Sun Pharmaceutical Industries

Drug Profile

Tildrakizumab - Almirall/Sun Pharmaceutical Industries

Alternative Names: ILUMETRI; Ilumetri; ILUMYA; MK-3222; SCH-900222; SUNPG 1622; SUNPG 1622 I; SUNPG 1623 I; SUNPG 1623 II; SUNPG 1623 III; SUNPG 1623 IV; SUNPG1623; Tildrakizumab-asmn

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Developer Almirall S.A.; Merck & Co; Schering-Plough; Sun Pharmaceutical Industries
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Phase II/III Ankylosing spondylitis; Psoriatic arthritis; Spondylarthritis
  • Discontinued Autoimmune disorders

Most Recent Events

  • 23 Oct 2018 Launched for Plaque psoriasis in USA (SC)
  • 21 Sep 2018 Registered for Plaque psoriasis in Australia (SC)
  • 19 Sep 2018 Registered for Plaque psoriasis in European Union, Iceland, Liechtenstein, Norway (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top